2269.HK

WuXi Biologics (Cayman) Inc. [2269.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

2269.HK Stock Summary

Earnings have grown 48.38% per last year.

Top 10 Correlated Stocks

2269.HK

In the News

2269.HK Financial details

Company Rating

Market Cap

59.2B

Income

4.15B

Revenue

16.55B

Book val./share

Cash/share

Dividend

Dividend %

Employees

12.74K

Optionable

Shortable

Yes

Earnings

22 Mar 2024

P/E

52.24

Forward P/E

PEG

32.55

P/S

12.13

P/B

2.98

P/C

P/FCF

108.63

Quick Ratio

1.07

Current Ratio

2.2

Debt / Equity

LT Debt / Equity

EPS (TTM)

0.94

EPS next Y

EPS next Q

EPS this Y

30.86%

EPS next Y

EPS next 5Y

EPS last 5Y

45.96%

Revenue last 5Y

43.21%

Revenue Q/Q

EPS Q/Q

SMA20

-0.88%

SMA50

16.37%

SMA100

19.27%

Inst Own

Inst Trans

ROA

ROE

ROC

0.06%

Gross Margin

41%

Oper. Margin

31%

Profit Margin

24%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

12.9-56.7

52W High

-52.41%

52W Low

+122.08%

RSI

58.82

Rel Volume

1.38

Avg Volume

68.52M

Volume

94.8M

Perf Week

3.9%

Perf Month

3.5%

Perf Quarter

51.42%

Perf Half Y

61.71%

Beta

0.623

Volatility

0.46%, 0.92%

Prev Close

3.7%

Price

26.65

Change

2.9%

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 68.52M
Market Capitalization 59.2B
Employee 12.74K
CEO Dr. Zhisheng Chen
Headquarters Wuxi,CN
IPO Date 2017-06-13
Website https://www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.